| Code | CSB-RA004929MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Felzartamab, targeting CD38, a type II transmembrane glycoprotein that functions as both an ectoenzyme and a receptor. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and participates in calcium signaling, playing crucial roles in immune cell activation, proliferation, and migration. This protein is highly expressed on plasma cells, activated lymphocytes, and various hematopoietic cells, making it clinically relevant in multiple myeloma, chronic lymphocytic leukemia, and autoimmune conditions. Elevated CD38 expression is also associated with antibody-mediated rejection in transplantation settings.
Felzartamab represents a therapeutic antibody designed to deplete CD38-positive cells through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mechanisms. This biosimilar provides researchers with a valuable tool for investigating CD38-mediated pathways, studying plasma cell biology, exploring immunological mechanisms in autoimmune diseases, and evaluating potential therapeutic strategies in hematological malignancies and transplant rejection. The antibody enables comprehensive examination of CD38 function in both normal physiology and disease states.
There are currently no reviews for this product.